Slingshot members are tracking this event:

Phase 1 updated data of Agios'(AGIO) ivosidenib in IDH1 mutant newly diagnosed AML ineligible for standard therapies presented at ASCO

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Clinical Data Safety Results
  • The most common Grade 3/4 adverse events (AEs) regardless of cause were thrombocytopenia (61%), anemia (44%), febrile neutropenia (44%) and neutropenia (30%).
  • Investigator reported IDH differentiation syndrome was reported in four patients, of which three were serious AEs. All four cases resolved, among whom two achieved a complete response (CR), one stable disease and one was not evaluable for response.
  • Mean neutrophil and platelet counts were maintained near or above thresholds for CR with partial hematologic recovery (CRh) while on study treatment with TIBSOVO® and azacitidine. CRh is defined as <5% of blasts in the bone marrow, no evidence of disease and partial recovery of peripheral blood counts (ANC >500/microliter and platelets >50,000/microliter).
Efficacy Results
  • Overall, 78% (18/23) of patients had a response.
  • 70% (16/23) of patients had a CR or CRh.
  • 61% (14/23) of patients had a CR.
  • The median duration of CR (95% CI 9.3, NE) as well as CR+CRh (95% CI 12.2, NE) had not been reached.
  • The median time to response was 1.8 months (range 0.7-3.8 months) and the median time to CR was 3.7 months (range 0.8-15.7 months).
  • The 12-month survival rate was 82% (95% CI 58.8, 92.8).
  • The median duration of follow-up was 16.1 months (range 1.3-31.7 months).
  • For patients who achieved a CR, IDH1 mutation clearance was observed in 9 of 14 (64%) patients with available bone marrow mononuclear cells (BMMCs) and 11 of 14 patients (79%) with available peripheral blood mononuclear cells (PBMCs) as quantified by a digital PCR assay with lower limit of sensitivity for mutant IDH1 of 0.02-0.04% (or 10-4).
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Idh1 Mutation, Ivosidenib, Aml, Acute Myeloid Leukemia